ImmuPharma (LON:IMM) Stock Price Down 10% – What’s Next?

ImmuPharma plc (LON:IMM) was down 10% on Monday . The stock traded as low as GBX 11.25 ($0.15) and last traded at GBX 11.25 ($0.15). Approximately 6,973,006 shares changed hands during mid-day trading, a decline of 18% from the average daily volume of 8,490,692 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Stock Down 3.3%

The firm has a market cap of £58.47 million, a price-to-earnings ratio of -1,314.61 and a beta of 1.53. The stock has a 50 day moving average of GBX 4.66 and a 200 day moving average of GBX 3.39.

ImmuPharma (LON:IMM) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.